Business Context and Reporting Period
Neurocrine Biosciences, Inc. filed a Form 8-K on December 20, 2024, to announce the commercial launch of CRENESSITY (crinecerfont) in the United States. The drug is approved by the FDA as an adjunctive treatment to glucocorticoid replacement for controlling androgens in adult and pediatric patients (four years and older) with classic congenital adrenal hyperplasia.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on product launch details and pricing.
- Wholesale Acquisition Cost (Adults): Approximately $38,333 for a 30-day supply.
- Wholesale Acquisition Cost (Pediatric <20kg): Approximately $19,167 for a 30-day supply.
- Patient Copay Expectation: The Company expects 90% of patients to have a monthly copay of $12 or less.
Material Changes
The primary material change is the transition of CRENESSITY from regulatory approval to active commercial availability in the U.S. market as of December 20, 2024.
Outlook, Risks, and Management Commentary
Management highlighted the availability of the product and established pricing structures. The filing includes forward-looking statements regarding potential benefits, patient access, and reimbursement expectations. Key risks identified include:
- Uncertainty regarding adequate reimbursement from third-party payors.
- Dependence on third parties for development and manufacturing activities.
- General risks associated with the commercialization of CRENESSITY.
Investor Verification Checklist
- Verify the actual reimbursement rates and coverage policies from major third-party payors compared to the Company's expectation of low patient copays.
- Monitor initial sales volume and market penetration rates following the December 20, 2024 launch.
- Review the Company's periodic reports (e.g., Form 10-Q) for details on manufacturing capacity and third-party agreements.